CASI
Price
$1.94
Change
+$0.01 (+0.52%)
Updated
Apr 17 closing price
Capitalization
30.04M
KALA
Price
$3.46
Change
-$0.02 (-0.58%)
Updated
Apr 17 closing price
Capitalization
22.29M
Ad is loading...

CASI vs KALA

Header iconCASI vs KALA Comparison
Open Charts CASI vs KALABanner chart's image
CASI Pharmaceuticals
Price$1.94
Change+$0.01 (+0.52%)
Volume$16.8K
Capitalization30.04M
Kala BIO
Price$3.46
Change-$0.02 (-0.58%)
Volume$13.67K
Capitalization22.29M
CASI vs KALA Comparison Chart
Loading...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CASI vs. KALA commentary
Apr 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CASI is a Hold and KALA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 18, 2025
Stock price -- (CASI: $1.94 vs. KALA: $3.45)
Brand notoriety: CASI and KALA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CASI: 161% vs. KALA: 26%
Market capitalization -- CASI: $30.04M vs. KALA: $22.29M
CASI [@Biotechnology] is valued at $30.04M. KALA’s [@Biotechnology] market capitalization is $22.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CASI’s FA Score shows that 0 FA rating(s) are green whileKALA’s FA Score has 0 green FA rating(s).

  • CASI’s FA Score: 0 green, 5 red.
  • KALA’s FA Score: 0 green, 5 red.
According to our system of comparison, KALA is a better buy in the long-term than CASI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CASI’s TA Score shows that 4 TA indicator(s) are bullish while KALA’s TA Score has 4 bullish TA indicator(s).

  • CASI’s TA Score: 4 bullish, 4 bearish.
  • KALA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CASI and KALA are a good buy in the short-term.

Price Growth

CASI (@Biotechnology) experienced а +1.51% price change this week, while KALA (@Biotechnology) price change was +1.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

CASI is expected to report earnings on May 17, 2023.

KALA is expected to report earnings on May 09, 2023.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CASI($30M) has a higher market cap than KALA($22.3M). CASI YTD gains are higher at: -31.488 vs. KALA (-50.216). CASI (-31.62M) and KALA (-32.84M) have comparable annual earnings (EBITDA) . KALA has more cash in the bank: 49.2M vs. CASI (20.8M). CASI has less debt than KALA: CASI (19.1M) vs KALA (37M). CASI has higher revenues than KALA: CASI (22.1M) vs KALA (0).
CASIKALACASI / KALA
Capitalization30M22.3M135%
EBITDA-31.62M-32.84M96%
Gain YTD-31.488-50.21663%
P/E RatioN/AN/A-
Revenue22.1M0-
Total Cash20.8M49.2M42%
Total Debt19.1M37M52%
FUNDAMENTALS RATINGS
CASI vs KALA: Fundamental Ratings
CASI
KALA
OUTLOOK RATING
1..100
2352
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8595
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALA's Valuation (57) in the Pharmaceuticals Major industry is in the same range as CASI (77) in the Biotechnology industry. This means that KALA’s stock grew similarly to CASI’s over the last 12 months.

KALA's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CASI (100) in the Biotechnology industry. This means that KALA’s stock grew similarly to CASI’s over the last 12 months.

CASI's SMR Rating (99) in the Biotechnology industry is in the same range as KALA (100) in the Pharmaceuticals Major industry. This means that CASI’s stock grew similarly to KALA’s over the last 12 months.

CASI's Price Growth Rating (85) in the Biotechnology industry is in the same range as KALA (95) in the Pharmaceuticals Major industry. This means that CASI’s stock grew similarly to KALA’s over the last 12 months.

KALA's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as CASI (100) in the Biotechnology industry. This means that KALA’s stock grew similarly to CASI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CASIKALA
RSI
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
78%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
CASI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
BTC.X84895.750000861.882800
+1.03%
Bitcoin cryptocurrency
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla

CASI and

Correlation & Price change

A.I.dvisor tells us that CASI and ATRA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASI and ATRA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASI
1D Price
Change %
CASI100%
+0.46%
ATRA - CASI
31%
Poorly correlated
+5.65%
RIGL - CASI
30%
Poorly correlated
+2.18%
VICP - CASI
29%
Poorly correlated
N/A
AVXL - CASI
26%
Poorly correlated
+1.24%
AURA - CASI
25%
Poorly correlated
-0.74%
More

KALA and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALA has been loosely correlated with ABCZF. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KALA jumps, then ABCZF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALA
1D Price
Change %
KALA100%
-0.43%
ABCZF - KALA
42%
Loosely correlated
N/A
VICP - KALA
29%
Poorly correlated
N/A
KLTO - KALA
27%
Poorly correlated
+1.67%
CRGX - KALA
27%
Poorly correlated
N/A
ORIC - KALA
27%
Poorly correlated
+1.71%
More